Effective human engagement at all levels - financial, scientific, research - is essential to success in the biotech industry.
In this episode, Matthew Price talks about Promontory's journey in the biotech industry, the potential of PT-112 as an immunogenic cell death inducer, and the complexities of conducting cancer research and clinical trials. Matthew also addresses challenges in translating preclinical findings to human trials, supporting patient commitment, COVID-19's impact on clinical research, and the company's funding goals.
Tune in to learn more about how Promontory navigates the translation of preclinical success to human trials focusing on human relationships and experiences!
Click this link to the show notes, transcript, and resources: outcomesrocket.health
Outcomes Rocket